Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


Delayed Quote. Delayed  - 09/27 05:35:13 pm
88.78 EUR   -0.47%
09/26 NEW CLINICAL GU : -- Iberogast™ recommended for the treatment ..
09/26DJLanxess Shares Rise on Acquisition of Chemtura
09/25 POLITICAL NOTES : Garamendi sends condolences
News SummaryMost relevantAll newsSector news 

Bayer Stops Sale of Glucose Meter Business

share with twitter share with LinkedIn share with facebook
share via e-mail
01/09/2013 | 12:07pm CEST

By Hendrik Varnholt

FRANKFURT--German pharmaceutical company Bayer AG (>> Bayer AG) will retain its blood glucose meter business, a spokeswoman said Wednesday, confirming a Bloomberg report.

Bayer had put up the unit for sale and had been in talks with French peer Sanofi SA (>> SANOFI) about a deal which could have been valued at around $1.5 billion, people familiar with the matter told Dow Jones Newswires in December.

"We have evaluated several options and decided to retain it," Bayer HealthCare chief Joerg Reinhardt said about the glucose meter business, according to Bloomberg.

Natali Schwab, Eyk Henning and Dana Cimilluca contributed to this story.

Write to Hendrik Varnholt at hendrik.varnholt@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bayer AG, SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
09/26 NEW CLINICAL GUIDELINES : -- Iberogast™ recommended for the treatment of f..
09/26DJLanxess Shares Rise on Acquisition of Chemtura
09/25 POLITICAL NOTES : Garamendi sends condolences
09/24 BAYER : buys Monsanto for $66 bln
09/23 BAYER : Flupyradifurone; Pesticide Tolerances
09/23 BAYER AT EUROTIER 2016 : -- Animal Health and Crop Protection from a single sour..
09/23 BAYER : New scholarships worth EUR 345,000 awarded by Bayer Foundation to promot..
09/22 BAYER : partners Bright Future Fund to improve access to innovative treatment fo..
09/22 MONSANTO : and industry execs defend wave of agribusiness mega-mergers
09/21 MONSANTO : and Bayer defend proposed $66 billion merger
More news
Sector news : Pharmaceuticals - NEC
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/27 Disney Prepping Twitter Bid
09/26 Monsanto/Bayer Merger Difficult, But Could Send MON Higher
09/22 Biontech Deal Sees Roche Bet On mRNA
09/22 Expect Glaxo To Increase Consumer Focus As Walmsley Takes Driving Seat
09/21 Bayer-Monsanto tie-up pilloried in Germany, U.S.
Financials (€)
Sales 2016 46 951 M
EBIT 2016 8 152 M
Net income 2016 4 764 M
Debt 2016 15 414 M
Yield 2016 3,00%
P/E ratio 2016 15,97
P/E ratio 2017 13,80
EV / Sales 2016 1,90x
EV / Sales 2017 1,76x
Capitalization 73 764 M
More Financials
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 108 €
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-23.33%82 947
JOHNSON & JOHNSON16.06%322 232
ROCHE HOLDING LTD.-12.41%215 081
NOVARTIS AG-10.14%211 231
PFIZER INC.4.80%204 049
MERCK & CO., INC.18.46%171 858
More Results